INTRODUCTION
The HER2/neu oncogene is a member of the epidermal growth factor receptor family, and its amplification is known to be one of the most common genetic alterations associated with human breast cancer. They emphasized that the performance of a testing algorithm should rely on an accurate, reproducible assay. They specified elements to reduce assay variation such as spec-Purpose: Silver-enhanced in situ hybridization (SISH) is a newly developed method to evaluate HER2 gene amplification in invasive breast carcinomas. Most laboratories widely use fluorescence in situ hybridization (FISH) to evaluate the HER2 gene amplification status because FISH is a very sensitive and accurate technique. However, this technique is not the best because it requires specialized equipment and interpretation skills. We compared a new technique of SISH with FISH for assessing HER2 gene amplification in invasive breast carcinomas. Methods: HER2 gene amplification was assessed in 165 cases of invasive breast carcinoma by FISH and SISH with constructing a tissue microarray. The tumors were assessed by the guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/ CAP). Positivity was defined as a HER2/Chromosome 17 ratio greater than 2.2. Negativity was defined if the ratio was less than 1.8. The tumor was considered as equivocal for HER2 gene amplification if the ratio was between 1.8 and 2.2. The HER2 protein status was assessed. Immunostaining for HER2 protein was performed in a Benchmark automatic immunostaining device with using whole tissue sections. Results: There was agreement of the HER2 gene amplification status by SISH and FISH in 162 of 165 cases, which is a concordance rate of 98.2% (κ =0.94). There were three discrepant cases, with two of them being FISH positive and SISH negative (one case was IHC negative and one case was IHC positive) and one case was FISH negative and SISH equivocal. Conclusion: The 98.2% concordance between FISH and SISH meets the ASCO/CAP requirements for test validation of >95% concordance. These results indicate that SISH can be used as an alternative to FISH for assessing the HER2 gene amplification status in breast carcinomas. 
METHODS

Case selection
Construction of tissue microarray blocks
Silver-enhanced in situ hybridization
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Statistics
Cases that yielded informative results with both techniques were only included in the concordance analyses. Concordance rates between IHC, FISH and SISH were determined and the κstatistics calculated by Cohen' s κ .
SISH and FISH for Her2 Gene Status 237 Figure 1 . Typical example of a non-amplified case and amplified case as demonstrated by Silver-enhanced in situ hybridization (SISH). (A) Two single dots represent each Chr17, (B) non-amplified HER2 case showed 2 HER2 signals in tumor cells (arrow), (C) amplified HER2 case showed clusters of HER2 signals in tumor cells (arrow). Note the fibroblasts (arrow head) as internal control (×1,000). (Table 3 ).
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RESULTS
DISCUSSION
The major aim of this study was to compare SISH to FISH assays presently used in diagnostic pathology laboratories and thus validate its use as a routine diagnostic method for assessing HER2 status in breast cancers. In this study, 11 out of 186 cases having evaluable tumor cells on the slides of SISH (5.9%) showed poor SISH staining. The tumor cell and internal control cells (fibroblast and endothelial cells) had no signals. Also in same tissue microarray slide, there was some heterogeneous staining intensity in the sample. Judging from the fact that each two cores from the same case had similar intensity, the poor staining and heterogeneous intensity might be caused by a problem in the procedure for tissue processing.
The response of the Herceptin in the discrepant cases may be important to determine the reliability of the test.
However, because this study was done with the patients who were treated before Herceptin was used for the breast cancer treatment, the response could not be followed.
CONCLUSION
The concordance between SISH and FISH was excellent.
SISH is a fully automated technique and can be easily integrated into routine testing for breast cancer biomarkers as an alternative to FISH for determination of HER2 status in breast carcinoma.
